Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.32 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.32 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310615 | 0.92 | MAP4K1 (0.33) | MAP4K1 | |
| SCHEMBL24309865 | 0.88 | EGFR (0.33) | — | |
| SCHEMBL24310341 | 0.86 | SCN9A (0.38) | DYRK1ACACNA2D1CLK1CLK2HIPK1 | |
| SCHEMBL29566911 | 0.86 | SCN9A (0.38) | DYRK1ACACNA2D1CLK1CLK2HIPK1 | |
| SCHEMBL24310359 | 0.80 | BRD9 (0.34) | — | |
| SCHEMBL24310367 | 0.79 | ALK (0.31) | — | |
| SCHEMBL24310226 | 0.79 | DYRK1A (0.34) | DYRK1ACACNA2D1CLK1CLK2HIPK1 | |
| SCHEMBL24310616 | 0.78 | HTR1A (0.34) | MAP4K1DRD2 | |
| SCHEMBL29567020 | 0.78 | HTR1A (0.34) | MAP4K1DRD2 | |
| SCHEMBL24309710 | 0.77 | FLT4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |